Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines. Its development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV. The company is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VXRT
CUSIPN/A
Phone650-550-3500
Debt
Debt-to-Equity Ratio0.10
Current Ratio4.09
Quick Ratio4.09
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$8.90 million
Price / Sales2.49
Cash FlowN/A
Price / CashN/A
Book Value$5.32 per share
Price / Book0.58
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-29,400,000.00
Net Margins-286.74%
Return on Equity-202.17%
Return on Assets-37.17%
Miscellaneous
Employees16
Outstanding Shares7,140,000
Market Cap$23.07
Vaxart (NASDAQ:VXRT) Frequently Asked Questions
What is Vaxart's stock symbol?
Vaxart trades on the NASDAQ under the ticker symbol "VXRT."
When did Vaxart's stock split? How did Vaxart's stock split work?
Vaxart shares reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.
How were Vaxart's earnings last quarter?
Vaxart Inc (NASDAQ:VXRT) released its quarterly earnings data on Tuesday, May, 15th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter. The biotechnology company had revenue of $1.50 million for the quarter. Vaxart had a negative return on equity of 202.17% and a negative net margin of 286.74%. View Vaxart's Earnings History.
What is the consensus analysts' recommendation for Vaxart?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
Who are some of Vaxart's key competitors?
Some companies that are related to Vaxart include Brainstorm Cell Therapeutics (BCLI), Champions Oncology (CSBR), Applied Genetic Technologies (AGTC), Entera Bio (ENTX), Genocea Biosciences (GNCA), Curis (CRIS), BioCardia (BCDA), Aevi Genomic Medicine (GNMX), TRACON Pharmaceuticals (TCON), Arsanis (ASNS), Proteon Therapeutics (PRTO), BIONDVAX PHARMA/S (BVXV), CytRx (CYTR), Microbot Medical (MBOT) and Oncobiologics (ONS).
Who are Vaxart's key executives?
Vaxart's management team includes the folowing people:
- Dr. Wouter W. Latour M.B.A., M.D., MBA, Pres, CEO & Director (Age 60)
- Dr. Sean N. Tucker, Founder & Chief Scientific Officer (Age 50)
- Mr. John M. Harland M.B.A., CPA, CFO & Sec. (Age 66)
- Mr. Brant Biehn, Sr. VP of Commercial Operations
- Dr. David N. Taylor, Chief Medical Officer (Age 69)
Has Vaxart been receiving favorable news coverage?
Media headlines about VXRT stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vaxart earned a news sentiment score of 0.08 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 45.48 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Vaxart?
Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vaxart's stock price today?
One share of VXRT stock can currently be purchased for approximately $3.11.
How big of a company is Vaxart?
Vaxart has a market capitalization of $23.07 million and generates $8.90 million in revenue each year. Vaxart employs 16 workers across the globe.
How can I contact Vaxart?
Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected]
MarketBeat Community Rating for Vaxart (NASDAQ VXRT)
MarketBeat's community ratings are surveys of what our community members think about Vaxart and other stocks. Vote "Outperform" if you believe VXRT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VXRT will underperform the S&P 500 over the long term. You may vote once every thirty days.
